Découvrez ce que disent vraiment les chiffres — avant le marché
Analyser maintenant
Sentiment des actualités
Les actualités d’aujourd’hui sont-elles un signal d’achat ou un avertissement ?
Analyser maintenant
Acheter / Conserver / Vendre
Faut-il acheter, conserver ou vendre ? Obtenez l’avis de l’IA dès maintenant.
Analyser maintenant
Évaluation des risques
Détectez les risques cachés avant qu’ils n’impactent votre portefeuille.
Analyser maintenant
Juste valeur
Cette action est-elle bon marché, correctement valorisée ou surévaluée ?
Analyser maintenant
Dernières analyses d’IA sur BIOPHYTIS NAM.
Résumé de la Note des Analystes
Achat
Achat fort
Achat
Conserver
Vente
Vente forte
0
1
0
0
0
Pas de cours
Cours de clôture XPAR 29.04.2026:
0,02 EUR
29.04.2026 15:21
Cours actuels de BIOPHYTIS NAM.
Bourse
Ticker
Devise
Dernier échange
Cours
Variation journalière
Paris
ALBPS.PA
EUR
29.04.2026 15:21
0,02 EUR
-0,003 EUR
-11,11 %
Flottant et Liquidité des Actions
Flottant Libre100,54 %
Actions en Flottant23,36 M
Actions en Circulation23,23 M
Profil de l'entreprise pour BIOPHYTIS NAM. Action
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.
